BAM Wealth Management LLC Invests $704,000 in Zoetis Inc. $ZTS

BAM Wealth Management LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,814 shares of the company’s stock, valued at approximately $704,000.

Several other large investors have also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Zoetis in the second quarter worth $809,491,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after purchasing an additional 1,995,491 shares during the period. Corient Private Wealth LLC grew its stake in Zoetis by 85.9% during the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after purchasing an additional 1,191,840 shares in the last quarter. Impax Asset Management Group plc increased its holdings in Zoetis by 362.6% during the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after purchasing an additional 922,589 shares during the period. Finally, Swedbank AB raised its position in Zoetis by 60.4% in the 3rd quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock valued at $356,565,000 after purchasing an additional 917,598 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Wednesday, December 3rd. Piper Sandler reiterated a “neutral” rating and set a $135.00 target price (down previously from $190.00) on shares of Zoetis in a research note on Thursday. Finally, Barclays initiated coverage on Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $124.04 on Friday. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.40. The firm has a market capitalization of $54.66 billion, a P/E ratio of 20.88, a P/E/G ratio of 2.16 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The company’s fifty day moving average price is $123.58 and its 200 day moving average price is $138.43.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter last year, the company posted $1.58 earnings per share. The business’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be paid a $0.53 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Tuesday, January 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.